Journal
BRITISH JOURNAL OF CANCER
Volume 96, Issue 3, Pages 445-449Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6603596
Keywords
melanoma; Ki67; biomarker; BRAF; MAP kinase; Akt
Categories
Funding
- NCI NIH HHS [R01 CA076674, R01 CA080999, CA 098101, CA 80999, CA 93372, P30 CA010815, R01 CA047159, CA 76674, P01 CA025874, CA 10815, P01 CA098101, P50 CA093372, CA 25874, CA 47159] Funding Source: Medline
- NIGMS NIH HHS [R01 GM071695, GM071695] Funding Source: Medline
Ask authors/readers for more resources
The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
